Evaluation of the antimicrobial activity of a pyrimidine compound 2-methyl-3-(2-phenyl-2-oxoethyl) quinazolin-4(3H)-on against Klebsiella pneumoniae under in vivo conditions

The greatest danger is the development of multiple antimicrobial resistance in microorganisms, including Klebsiella pneumoniae, which actualizes the necessity of development and synthesis of new antimicrobial compounds. Considering the versatile pharmacological activity, pyrimidine compounds became a subject of interest for scientists in the aspect of their use as a basis for new antimicrobial agents.

Aim: To assess the antimicrobial activity of the pyrimidine compound 2-Methyl-3-(2-phenyl-2-oxoethyl)quinazoline-4(3H)-on against Kl. pneumoniae under in vivo conditions.

Material and Methods. The antimicrobial activity in vivo of the compound 2-Methyl-3-(2-phenyl-2-oxoethyl)quinazolin-4(3H)-on against Kl. pneumoniae was performed simulating generalized infection by intraperitoneal injection of the pathogen at a dose of 3 × 10⁶. The experiment was conducted on CBA line mice (40 animals) divided into groups: control I – animals received intraperitoneal injection water; control II – infected animals received no treatment; experimental groups – mice with generalized infection treated with ceftriaxone at the dose 50 mg/kg intraperitoneally for 7 days, and the animals receiving the test compound at the dose 27 mg/kg against infection in the same mode. Antimicrobial activity was assessed by the following parameters: animal survival rate; internal organ and blood infestation index; total leukocyte count, C-reactive protein and procalcitonin.

Results. It was found that pyrimidine derivative 2-Methyl-3-(2-phenyl-2-oxoethyl)quinazoline-4(3H)-on has a marked antimicrobial activity against Kl. pneumonia appeared in increase of animal survival in the conditions of generalized Klebsiella infection as well as in decrease of total leukocyte count, C-reactive protein and procalcitonin levels that confirms the reduction of the inflammatory reaction.

Conclusion. Thus, the pyrimidine derivative 2-Methyl-3-(2-phenyl-2-oxoethyl)quinazoline-4(3H)-on exhibits antimicrobial activity, comparable with ceftriaxone, against Klebsiella pneumoniae in experimental generalized Klebsiella infection.

1. Mancuso G., Midiri A., Gerace E., Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021;10(10):1310. DOI: 10.3390/pathogens10101310.

2. Peterson E., Kaur P. Antibiotic resistance mechanisms in bacteria: relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens. Frontiers in Microbiology. 2018;9:2928. DOI: 10.3389/fmicb.2018.02928.

3. Aslam B., Wang W., Arshad M.I., Khurshid M., Muzammil S., Rasool M.H. et al. Antibiotic resistance: a rundown of a global crisis. Infection and drug resistance. 2018;11:1645. DOI: 10.2147/IDR.S173867.

4. Khaertynov K.S., Anokhin V.A., Rizvanov A.A., Davidyuk Y.N., Semyenova D.R., Lubin S.A. et al. Virulence factors and antibiotic resistance of Klebsiella pneumoniae strains isolated from neonates with sepsis. Frontiers in Medicine. 2018;5:225. DOI: 10.3389/fmed.2018.00225.

5. Ясенявская А.Л., Цибизова А.А., Озеров А.А., Тюренков И.Н., Башкина О.А., Самотруева М.А. Оценка иммунотоксических свойств производных пиримидина. Иммунология. 2022;43(3):312–319. DOI: 10.33029/0206-4952-2022-43-3-312-319.

6. Zhuang J., Ma S. Recent development of pyrimidine-containing antimicrobial agents. Chem. Med.Chem. 2020;15(20):1875–1886. DOI: 10.1002/cmdc.202000378.

7. Sayed M., Kamal El-Dean A.M., Ahmed M., Hassanien R. Design, synthesis, and characterization of novel pyrimidines bearing indole as antimicrobial agents. J. Chin. Chem. Soc. 2019;66(2):218–225. DOI: 10.1002/jccs.201800115.

8. Verma V., Joshi C. P., Agarwal A., Soni S., Kataria U. A review on pharmacological aspects of pyrimidine derivatives. Journal of Drug Delivery and Therapeutics. 2020;10(5):358–361. DOI: 10.22270/jddt.v10i5.4295.

9. Bhat A. R., Dongre R. S., Almalki F. A., Berredjem M., Aissaoui M., Touzani R. et al. Synthesis, biological activity and POM/DFT/docking analyses of annulated pyrano [2, 3-d] pyrimidine derivatives: Identification of antibacterial and antitumor pharmacophore sites. Bioorganic Chemistry. 2021;106:104480. DOI: 10.1016/j.bioorg.2020.104480.

10. Naresh Kumar R., Jitender Dev G., Ravikumar N., Krishna Swaroop D., Debanjan B., Bharath G. et al. Synthesis of novel triazole/isoxazole functionalized 7-(trifluoromethyl)pyrido[2,3-d]pyrimidine derivatives as promising anticancer and antibacterial agents. Bioorg. Med. Chem. Lett. 2016;26(12):2927–2930. DOI: 10.1016/j.bmcl.2016.04.038.

11. Suresh L., Sagar Vijay Kumar P., Poornachandra Y., Ganesh Kumar C., Babu N. J., Chandramouli G.V.P. An expeditious four-component domino protocol for the synthesis of novel thiazolo[3,2-a]thiochromeno[4,3-d]pyrimidine derivatives as antibacterial and antibiofilm agents. Bioorg. Med. Chem. 2016;24:3808–3817. DOI: 10.1016/j.bmc.2016.06.025.

12. Savateev K.V., Ulomsky E.N., Fedotov V.V., Rusinov V.L., Sivak K.V., Lyubishin M.M. et al. 6-Nitrotriazolo[1,5-a ]pyrimidines as promising structures for pharmacotherapy of septic conditions. Russ. J. Bioorg. Chem. 2017;43:421–428. DOI: 10.1134/S1068162017040094.